Viking Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Viking Therapeutics, Inc. (VKTX) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $62.30 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2018-05-09
- Viking Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-03-31 was $62.30M, a 2368.23% increase year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-12-31 was $14.76M, a 1321.96% increase year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-09-30 was $1.11M, a 925.01% increase year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-06-30 was $4.00M, a 56.78% decline year-over-year.
- Viking Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for fiscal 2017 was $22.40M, a 116.46% increase from fiscal 2016.
- Viking Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $10.35M, a 53.42% decline from fiscal 2015.
- Viking Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $22.21M, a 924.80% increase from fiscal 2014.
- Viking Therapeutics, Inc. net cash provided by (used in) financing activities, continuing operations for fiscal 2014 was $2.17M.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | $62.30M 10-Q · filed 2018-05-09 | $77.06M derived: sum of 2 quarters · filed 2018-05-09 | $78.17M derived: sum of 3 quarters · filed 2018-05-09 | $82.17M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | $14.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $15.87M derived: sum of 2 quarters · filed 2018-03-07 | $19.88M derived: sum of 3 quarters · filed 2018-03-07 | $22.40M 10-K · filed 2018-03-07 | |
| 2017-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $5.11M derived: sum of 2 quarters · filed 2017-11-08 | $7.64M 10-Q · filed 2017-11-08 | $8.67M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $6.53M 10-Q · filed 2017-08-09 | $7.56M derived: sum of 3 quarters · filed 2018-05-09 | $7.67M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-03-31 | $2.52M 10-Q · filed 2018-05-09 | $2.52M 10-Q · filed 2017-05-10 | $3.56M derived: sum of 2 quarters · filed 2018-05-09 | $3.67M derived: sum of 3 quarters · filed 2018-05-09 | $12.93M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $1.15M derived: sum of 2 quarters · filed 2018-03-07 | $10.41M derived: sum of 3 quarters · filed 2018-03-07 | $10.35M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $108.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $9.37M derived: sum of 2 quarters · filed 2017-11-08 | $9.31M 10-Q · filed 2017-11-08 | $9.28M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2016-06-30 | $9.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $9.20M 10-Q · filed 2017-08-09 | $9.17M derived: sum of 3 quarters · filed 2017-08-09 | $8.47M derived: sum of 4 quarters · filed 2017-08-09 | |
| 2016-03-31 | -$57.30K 10-Q · filed 2017-05-10 | -$85.48K derived: sum of 2 quarters · filed 2017-05-10 | -$790.13K derived: sum of 3 quarters · filed 2017-05-10 | $22.17M derived: sum of 4 quarters · filed 2017-05-10 | |
| 2015-12-31 | -$28.18K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | -$732.83K derived: sum of 2 quarters · filed 2017-03-21 | $22.23M derived: sum of 3 quarters · filed 2017-03-21 | $22.21M 10-K · filed 2017-03-21 | |
| 2015-09-30 | -$704.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $22.26M derived: sum of 2 quarters · filed 2016-11-10 | $22.24M 10-Q · filed 2016-11-10 | $22.64M derived: sum of 4 quarters · filed 2016-11-10 | |
| 2015-06-30 | $22.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $22.95M 10-Q · filed 2016-08-11 | $23.35M derived: sum of 3 quarters · filed 2016-08-11 | $23.86M derived: sum of 4 quarters · filed 2016-08-11 | |
| 2015-03-31 | -$17.91K 10-Q · filed 2016-05-10 | $384.50K derived: sum of 2 quarters · filed 2016-05-10 | $897.26K derived: sum of 3 quarters · filed 2016-05-10 | $2.15M derived: sum of 4 quarters · filed 2016-05-10 | |
| 2014-12-31 | $402.41K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $915.16K derived: sum of 2 quarters · filed 2016-03-08 | $2.17M derived: sum of 3 quarters · filed 2016-03-08 | $2.17M 10-K · filed 2016-03-08 | |
| 2014-09-30 | $512.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.77M derived: sum of 2 quarters · filed 2015-11-05 | $1.77M 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.25M 10-Q · filed 2015-08-14 | |||
| 2014-03-31 | -$2.00 10-Q · filed 2015-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |